Kairos Pharma, LTD. — Director's Dealing 2025

Nov 26, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2025-10-08

Reporting Person: Singhvi Rahul (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-08	COMMON STOCK	A	19084	$0.00	Acquired	49204	Direct

Footnotes

F1: Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.

F2: Consists of 49,204 RSUs which remain subject to vesting.